{"id":3608,"date":"2015-06-04T14:04:02","date_gmt":"2015-06-04T13:04:02","guid":{"rendered":"https:\/\/perruchenautomne.eu\/wordpress\/?p=3608"},"modified":"2015-06-04T14:04:02","modified_gmt":"2015-06-04T13:04:02","slug":"le-tolvaptan-a-recu-un-accord-de-commercialisation-pour-le-traitement-de-la-polykystose-renale-autosomique-dominante-par-le-commission-europeenne","status":"publish","type":"post","link":"https:\/\/perruchenautomne.eu\/wordpress\/2015\/06\/04\/le-tolvaptan-a-recu-un-accord-de-commercialisation-pour-le-traitement-de-la-polykystose-renale-autosomique-dominante-par-le-commission-europeenne\/","title":{"rendered":"Le tolvaptan a re\u00e7u un accord de commercialisation pour le traitement de la polykystose r\u00e9nale autosomique dominante par le commission europ\u00e9enne"},"content":{"rendered":"<p>\u00c7a y est, nous allons pouvoir officiellement utiliser le tolvaptan pour traiter les patients porteurs de polykystose r\u00e9nale autosomique dominante avec un d\u00e9bit de filtration glom\u00e9rulaire sup\u00e9rieur \u00e0 30 ml\/mn. Vous trouverez les r\u00e9sultats de <a href=\"https:\/\/perruchenautomne.eu\/wordpress\/?p=1151\">TEMPO, ici<\/a> et les <a href=\"https:\/\/perruchenautomne.eu\/wordpress\/?p=1509\">limites l\u00e0<\/a>.<\/p>\n<p>Voil\u00e0 une bonne nouvelle pour les patients que l&rsquo;accessibilit\u00e9 \u00e0 la seule mol\u00e9cule ayant montr\u00e9 un b\u00e9n\u00e9fice sur la fonction r\u00e9nale dans cette maladie.<\/p>\n<p>Les effets secondaires ne sont pas \u00e0 n\u00e9gliger et le bilan h\u00e9patique devra \u00eatre surveill\u00e9. Pour tout savoir sur les vaptans pour pouvez jeter un coup d&rsquo;oeil <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMra1403672\">au NEJM du jour<\/a>. <a href=\"https:\/\/perruchenautomne.eu\/wordpress\/wp-content\/uploads\/2015\/06\/nejmra1403672.pdf\">nejmra1403672<\/a><\/p>\n<p>Je pense proposer ce traitement aux patients avec un volume r\u00e9nal important et un g\u00e9notype <em>PKD1<\/em>. L&rsquo;utilisation du <a href=\"http:\/\/www.ashg.org\/2014meeting\/abstracts\/fulltext\/f140121536.htm\">score de l&rsquo;\u00e9quipe de Brest<\/a> sera un bon guide pour choisir les patients \u00e0 haut risque de progression. Il inclut 4 crit\u00e8res, le genre, l&rsquo;HTA avant 35 ans, une manifestation urologique avant 35 ans et le g\u00e9notype.<\/p>\n<p>Attendons que la France accepte le remboursement et donne une AMM pour cette mol\u00e9cule avant de proposer \u00e0 nos patients d&rsquo;uriner quelques litres par jour.<\/p>\n<blockquote><p>Otsuka Pharmaceutical Co., Ltd. announced today that the European Commission has granted marketing authorisation for JINARC\u00ae (tolvaptan) for the t<\/p><\/blockquote>\n<p>Source\u00a0: <em><a href=\"http:\/\/www.businesswire.com\/news\/home\/20150527005747\/en\/OTSUKA%E2%80%99S-JINARC%C2%AE-FIRST-EVER-TREATMENT-APPROVED-EUROPE-ADULTS\">OTSUKA\u2019S JINARC\u00ae THE FIRST-EVER TREATMENT APPROVED IN EUROPE FOR ADULTS LIVING WITH ADPKD, A CHRONIC GENETIC KIDNEY DISEASE | Business Wire<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00c7a y est, nous allons pouvoir officiellement utiliser le tolvaptan pour traiter les patients porteurs de polykystose r\u00e9nale autosomique dominante avec un d\u00e9bit de filtration glom\u00e9rulaire sup\u00e9rieur \u00e0 30 ml\/mn. Vous trouverez les r\u00e9sultats de TEMPO, ici et les limites &hellip; <a href=\"https:\/\/perruchenautomne.eu\/wordpress\/2015\/06\/04\/le-tolvaptan-a-recu-un-accord-de-commercialisation-pour-le-traitement-de-la-polykystose-renale-autosomique-dominante-par-le-commission-europeenne\/\">Continuer la lecture <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[13,14],"tags":[1513,216,527,528],"class_list":["post-3608","post","type-post","status-publish","format-standard","hentry","category-medecine-2","category-nephrologie","tag-commission-europeenne","tag-polykystose-renale-autosomique-dominante","tag-tempo","tag-tolvaptan"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p1l1zM-Wc","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/posts\/3608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/comments?post=3608"}],"version-history":[{"count":1,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/posts\/3608\/revisions"}],"predecessor-version":[{"id":3610,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/posts\/3608\/revisions\/3610"}],"wp:attachment":[{"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/media?parent=3608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/categories?post=3608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/perruchenautomne.eu\/wordpress\/wp-json\/wp\/v2\/tags?post=3608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}